Conversion disorder, motor type.
Conditions
Interventions
Product Name: paroxetine
Pharmaceutical Form: Capsule*
INN or Proposed INN: paroxetine
CAS Number: 61869-08-7
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral
Sponsors
GGz Nijmegen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diagnosis of conversion disorder. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1) A neurological disorder that can fully explain the symptoms as concluded by neurological examination (MRI, EMG, etc.)* 2) Psychosis or delusion disorder (current or in the past) 3) Suicidality 4) Mental retardation 5) Substance abuse or dependence 6) Usage of paroxetine (current or in the past) 7) Usage of another antidepressant (current) 8) Usage of a drug which has known negative interaction effects with antidepressants 9) Difficulty to understand the Dutch language. * A concomitant neurological disorder is no exclusion criteria when symptoms are not fully explained by the condition and criteria for conversion disorder are met.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To examine the effectiveness of antidepressants and psychological interventions versus control in reducing conversion symptoms.;Secondary Objective: ;Primary end point(s): The main study parameters are improvement in intensity of conversion symptoms as measured with the VRMC (Moene et al. 2002), the number of conversion symptoms as measured with the SCID I and improvement on the Clinical Global Improvement Scale. | — |
Countries
Netherlands
Outcome results
None listed